Recipharm has launched ReciPredict, a platform for Quality by Design (QbD) designed to transform the landscape of drug product development, tech transfer and manufacturing.
 
With its combination and systematic application of material sciences, statistical tools and modeling and simulation, ReciPredict aims to deliver efficiency and reliability to the pharmaceutical industry by streamlining the product development cycle, from initial formulation through to manufacturing.
 
Dr. Uwe Hanenberg, PhD, Head of Product Implementation, said: “ReciPredict accelerates the journey of new drugs to the clinical stage by 3-6 months, substantially expediting the drug development process. It also offers significant cost savings by reducing API consumption by 30% to 70%. Another crucial advantage is that applying ReciPredict de-risks tech transfers by identifying the right parameters for best process robustness, consequently achieving consistent and high-quality results. This is a win-win for our customers and for patients, as it helps bring new drugs to market faster.”
 
ReciPredict combines data science and statistics with modeling and statistical tools. By leveraging advanced statistical models, ReciPredict connects critical process parameters, material attributes and drug product quality attributes. This comprehensive understanding enables Quality by Design with precise prediction of quality attributes based on material properties and process parameters.
 
ReciPredict can be utilized across various stages and aspects of drug development and manufacturing, including product development, trial design and DoE, data analysis, In Silico formulations, tech transfers and process & formulation optimization. ReciPredict is versatile and can be applied to all sites, products and technologies, making it ideal for any pharmaceutical company looking to enhance their drug development and manufacturing processes.